Sanxin Medtec(SZ:300453) Zhong Guo Jing Ji Wang·2025-08-20 06:12Core Viewpoint - The announcement from Sanxin Medical (300453.SZ) reveals a plan for significant share reductions by major shareholders, which will not affect the company's control or ongoing operations [1][3]. Shareholder Reduction Plan - Major shareholders, including controlling shareholder Peng Jiulian and other executives, plan to reduce their holdings by up to 4,093,642 shares, representing 0.7838% of the total share capital [1]. - Specific reduction intentions include: - Peng Jiulian: up to 2,300,000 shares (0.4404%) - Mao Zhiping: up to 743,412 shares (0.1424%) - Le Zhenrong: up to 393,500 shares (0.0753%) - Liu Ming: up to 167,300 shares (0.0320%) - Wang Ganying: up to 227,750 shares (0.0436%) - Leng Lingli: up to 131,030 shares (0.0251%) - Liu Bingrong: up to 130,650 shares (0.0250%) [1]. Current Shareholding Status - As of the announcement date, the shareholding status of the major shareholders is as follows: - Peng Jiulian: 9,309,659 shares (1.7826%) - Mao Zhiping: 2,973,650 shares (0.5694%) - Le Zhenrong: 1,574,000 shares (0.3014%) - Liu Ming: 669,200 shares (0.1281%) - Wang Ganying: 911,000 shares (0.1744%) - Leng Lingli: 524,120 shares (0.1004%) - Liu Bingrong: 822,600 shares (0.1575%) [2]. Impact on Company Control - The planned share reductions will not lead to a change in the company's control or affect its ongoing operations [3]. Fundraising Plans - Sanxin Medical plans to raise up to 530 million yuan through the issuance of convertible bonds, with proceeds allocated to various projects, including the expansion of production capacity for blood dialysis membranes and related equipment [3]. Historical Share Reduction - Peng Jiulian has previously reduced her holdings, with a total of 555,270 shares sold since December 2018, resulting in approximately 64.19 million yuan in cash [3][4].